Cite
The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib.
MLA
Chen, Kuan-Chih, et al. “The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib.” OncoTargets & Therapy, vol. 16, May 2023, pp. 317–26. EBSCOhost, https://doi.org/10.2147/OTT.S407301.
APA
Chen, K.-C., Huang, Y.-H., Hsu, K.-H., Tseng, J.-S., Chang, G.-C., & Yang, T.-Y. (2023). The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib. OncoTargets & Therapy, 16, 317–326. https://doi.org/10.2147/OTT.S407301
Chicago
Chen, Kuan-Chih, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Gee-Chen Chang, and Tsung-Ying Yang. 2023. “The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib.” OncoTargets & Therapy 16 (May): 317–26. doi:10.2147/OTT.S407301.